S&C’s Antitrust and European Competition Practices were recognized across the Firm’s New York, Washington, D.C., London and Brussels offices in Global Competition Review’s 2024 GCR 100 rankings.
GCR 100 is a comprehensive listing of the world’s leading competition practices, providing a quantitative and qualitative analysis of the law firms doing the most important antitrust work around the world.
S&C was ranked “Highly Recommended” in New York and Washington, D.C., earning recognition for some of the Firm’s most significant antitrust matters over the past year, including Seagen’s $43 billion acquisition by Pfizer and Amgen’s $27.8 billion purchase of Horizon Therapeutics. S&C was also ranked “Recommended” in the United Kingdom and Brussels. In addition to Amgen/Horizon and Pfizer/Seagen, GCR highlighted the Firm’s representation of Credit Suisse on the competition aspects of its $3.3 billion merger with UBS, for acting as co-counsel to VMware in its €55 billion acquisition by Broadcom, and for advising e& in its initial $4.4 billion investment in Vodafone and in its proposed increased investment in May 2023. Notably, S&C also advised e& in its acquisition of a majority stake in PPF Telecom Europe in August 2023.